Glioblastoma multiforme

E Vicipaedia
Jump to navigation Jump to search
Esculaap4.svg
Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.
Imago glioblastomatis cum falcem cerebri amota propter diffusionem tumorem.

Glioblastoma multiforme sive Glioblastoma[1] est species cancri cerebri, qui haud sanabilis est. Nam quinque annos post morbum inventum, solum 2 centesimae hominum hoc cancro laborantium supersunt.[2] Causae huius morbi adhuc ignotae sunt.

Symptomata[recensere | fontem recensere]

Generalia indefinitivaque symptomata sunt convulsiones novae vel adhuc incognitae, capitis dolor, nausea, vomitus, memoriae spoliatio, ac alia symptomata neurologica circumscripta[3], quamquam spectrum symptomatum de tumoris loco pendat; per haec symptomata se attollere aut celerrime queant, aut longe occultare.

Classificatio glioblastomatum[recensere | fontem recensere]

Classificatio ordinis mundi sanitarii (WHO) anni 2016 notat:

  • Glioblastomata IDH1 mutanda
    • Glioblastoma cellularum gigantium
    • Gliosarcoma
    • Glioblastoma epitheloidum
  • Glioblastoma IDH1, typi ferocis
  • Glioblastoma non alibi specificatum

Comparatio classificationis 2016 cum veta 2017 criteria genetica addita esse ostendit: IDH mutandum et typum ferocem[4].

Tractatio[recensere | fontem recensere]

Adhuc sanatio glioblastomatis restat difficilis et estimatur tumorem recursurum esse[5]. Therapia per resectionem neurochirurgicam, radiotherapiam, chemotherapiam, et medicamentum temozolomidi fit.

Formae tractationis adhuc vel non generaliter probatae[recensere | fontem recensere]

In scientia hodierna medica novas tractationis formas investigantur[6] ut, verbi gratia, inhibitores receptorii EphA3, inhibitores EGFR (includens anticorpora monoclonalia), inhibitores VGEF.

Interleukin 12[recensere | fontem recensere]

Interleukinum 12 (IL-12) est cytokinum cum effectibus contra cancrum. Nuper CHIOCCA et al. textui gliobastomatis genum IL-12 generantem applicaverunt[7].

Notae[recensere | fontem recensere]

  1. "Glioblastoma and Malignant Astrocytoma". American Brain Tumour Association (ABTA) 
  2. Bleeker, Fonnet E.; Molenaar, Remco J.; Leenstra, Sieger (2012). "Recent advances in the molecular understanding of glioblastoma". Journal of Neuro-Oncology 108 (1): 11–27 
  3. Alifieris C., Trafalis D. T. (Aug 2015). "Glioblastoma multiforme: Pathogenesis and Treatment". Pharmacology & Treatment 152 (63-82) 
  4. Komori T. (2017). "The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision". Neurologia medico-chirurgica 57 (7): 301-11 
  5. Gallego O. (Aug 2015). "Nonsurgical treatment of recurrent glioblastoma". Current oncology 22 (4): e273-81 
  6. Taylor O. G., Brzozowski J. S., Skelding K. A. (Sep 2019). "Glioblastoma Multiforme: An Overview of Emerging Therapeutic Targets". Frontiers in oncology 9: 963 .
  7. Chiocca E. A., Yu J. S., Lukas R. V., Solomon I. H., Ligon K. L., Nakashima H., Triggs D. A., Reardon D. A., Wen P. (Aug 2019). "Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 Trial". Science translational medicine 11 (505): eaaw5680 .

Nexus interni